play_arrow

keyboard_arrow_right

replay_10 skip_previous play_arrow skip_next forward_10
00:00 00:00
playlist_play chevron_left
volume_up
play_arrow

Diabetes Drugs: Bittersweet Truth of Patent Expiries

Kiran Somvanshi July 26, 2022


Background
share close

With the oral diabetes drugs market at Rs 13,000 crore and growing, a key diabetes medicine Sitagliptin going off patent means a sweet spot for all. How does the billion-dollar pharma industry see an opportunity in a market with the highest number of diabetes patients in the world. Host Kiran Somvanshi chats with Nithya Balasubramanian, Director at AB Bernstein, Sheetal Sapale, Marketing President РAWACS, and Vikas Dandekar, Editor РPharma at ET Prime.
Credits: CNBC-TV18

Credits : Producers: Vinay Joshi from The Economic Times and Soundarya Jayachandran from Aawaz. Sound editors: Indranil Bhattacharjee from the Economic Times and Swati Joshi from Aawaz Executive Producers : Arijit Barman and Anupria Bahadur from The Economic Times.